CN113660864A - 辅助饮料 - Google Patents
辅助饮料 Download PDFInfo
- Publication number
- CN113660864A CN113660864A CN202080021177.3A CN202080021177A CN113660864A CN 113660864 A CN113660864 A CN 113660864A CN 202080021177 A CN202080021177 A CN 202080021177A CN 113660864 A CN113660864 A CN 113660864A
- Authority
- CN
- China
- Prior art keywords
- beverage
- tea
- agar
- grams
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013361 beverage Nutrition 0.000 title claims abstract description 36
- 238000002595 magnetic resonance imaging Methods 0.000 claims abstract description 23
- 229920001817 Agar Polymers 0.000 claims abstract description 21
- 239000008272 agar Substances 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 235000013616 tea Nutrition 0.000 claims abstract description 16
- 240000004153 Hibiscus sabdariffa Species 0.000 claims abstract description 15
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 239000002872 contrast media Substances 0.000 claims abstract description 11
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 10
- 235000014633 carbohydrates Nutrition 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 240000000982 Malva neglecta Species 0.000 claims abstract description 8
- 235000000060 Malva neglecta Nutrition 0.000 claims abstract description 8
- 229920002472 Starch Polymers 0.000 claims abstract description 7
- 235000015092 herbal tea Nutrition 0.000 claims abstract description 7
- 239000001814 pectin Substances 0.000 claims abstract description 7
- 229920001277 pectin Polymers 0.000 claims abstract description 7
- 235000010987 pectin Nutrition 0.000 claims abstract description 7
- 210000000813 small intestine Anatomy 0.000 claims abstract description 7
- 239000008107 starch Substances 0.000 claims abstract description 7
- 235000019698 starch Nutrition 0.000 claims abstract description 7
- 235000007319 Avena orientalis Nutrition 0.000 claims abstract description 6
- 244000075850 Avena orientalis Species 0.000 claims abstract description 6
- 241000196324 Embryophyta Species 0.000 claims abstract description 4
- 244000269722 Thea sinensis Species 0.000 claims abstract 5
- -1 /or Species 0.000 claims abstract 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 29
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 21
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 18
- 235000010355 mannitol Nutrition 0.000 claims description 18
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 16
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 15
- 239000000594 mannitol Substances 0.000 claims description 15
- 229930195725 Mannitol Natural products 0.000 claims description 14
- 235000005979 Citrus limon Nutrition 0.000 claims description 12
- 244000131522 Citrus pyriformis Species 0.000 claims description 12
- 235000015197 apple juice Nutrition 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- 235000013311 vegetables Nutrition 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims description 2
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 235000021014 blueberries Nutrition 0.000 claims description 2
- 235000015190 carrot juice Nutrition 0.000 claims description 2
- 235000020971 citrus fruits Nutrition 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 2
- 239000000347 magnesium hydroxide Substances 0.000 claims description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 235000013525 pomegranate juice Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 abstract description 2
- 235000010419 agar Nutrition 0.000 description 13
- 241001122767 Theaceae Species 0.000 description 11
- 230000000968 intestinal effect Effects 0.000 description 10
- 239000008141 laxative Substances 0.000 description 10
- 230000002475 laxative effect Effects 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000003204 osmotic effect Effects 0.000 description 6
- 238000012631 diagnostic technique Methods 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 241000206572 Rhodophyta Species 0.000 description 4
- 229940125722 laxative agent Drugs 0.000 description 4
- 210000003097 mucus Anatomy 0.000 description 4
- 230000008855 peristalsis Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 229920000715 Mucilage Polymers 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 229910052788 barium Inorganic materials 0.000 description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000020345 hibiscus tea Nutrition 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000001543 purgative effect Effects 0.000 description 2
- 230000002966 stenotic effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101100272279 Beauveria bassiana Beas gene Proteins 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021333 Ileus paralytic Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000011846 endoscopic investigation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003636 fecal output Effects 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 201000007620 paralytic ileus Diseases 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 206010036784 proctocolitis Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000002516 toxic megacolon Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/68—Acidifying substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/015—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/256—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seaweeds, e.g. alginates, agar or carrageenan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/37—Sugar alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Botany (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
- Non-Alcoholic Beverages (AREA)
- Tea And Coffee (AREA)
- Confectionery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Jellies, Jams, And Syrups (AREA)
Abstract
一种辅助饮料,其包含水基混合物,所述水基混合物包含80‑85重量/重量%的水、0.2‑0.5重量/重量%的盐、0.2‑0.5重量/重量%的琼脂和/或植物果胶和/或淀粉、0.3‑0.5重量/重量%的玫瑰茄茶和/或含有锦葵和/或燕麦的草本茶、15‑20重量/重量%的简单碳水化合物、0.1‑0.3重量/重量%的至少一种酸化剂。该辅助饮料可用作口服造影剂,用于肠系膜小肠的磁共振成像(肠‑MRI)实施。
Description
本发明的技术领域
本发明涉及一种辅助饮料(adjuvant beverage)。
更具体地说,本发明涉及一种辅助饮料,其作为口服造影剂对肠系膜小肠(mesenteric small intestine)成像实施特别有效,尤其是在磁共振成像中。
现有技术说明
肠系膜小肠的磁共振成像(MRI)也称为“肠-MRI”,是用于观察和研究小肠的诊断技术(否则,即使采用专门依靠使用视频胶囊的窥镜技术,小肠也难以通过成像进行检查和评估)。
事实上,胃十二指肠镜可以扫描胃和十二指肠,而结肠镜只能扫描结肠。
因此,肠-MRI(Entero-MRI)是一种使用最新一代磁共振设备的创新方法,该方法允许评估所有肠道病症,包括炎症(肠炎)和肿瘤。
具体来说,肠-MRI是用于慢性炎症性肠道疾病如(但不限于)克罗恩病和溃疡性直肠结肠炎(ulcerative rectal colitis)评估和随访的参考技术。
这种类型的检查现在已经取代了传统的小肠检查技术,例如用钡剂(连续小肠检查(serial small bowel))。
事实上,与上述技术相比,肠-MRI不使用辐射,患者的耐受性更好,并且允许获得更多的信息内容。
更详细地说,用钡剂的系列研究允许使肠腔不透明,因此,仅评估影响肠壁的任何病状对肠腔的影响:换言之,采用该技术仅可以识别可能的肠壁病状的间接征象。
另一方面,肠-MRI允许人们直接查看肠壁及其各层,因此能够直接研究任何病状的起病部位(onset site)。
还应注意的是,与传统检查不同,肠-MRI还允许评估肠附近的整个区域,包括腹盆区的血管、淋巴结、肠系膜和主要器官。
因此,由于磁共振技术的不断改进,一些肠-MRI序列目前也允许对肠道蠕动(即小肠运动,其在某些病状中会发生改变)进行动态评估。
最后、但并非最不重要的是,通过肠-MRI,可以识别任何小肠肿瘤病变。
这是该方法非常重要的特征,因为小肠肿瘤病灶仅很少(在10%的病例中)有症状,因此在大多数情况下,其在很长一段时间内完全不会被发现。
然而,使用肠磁共振成像技术有一些缺点。
这是用于口服的造影剂,由于许多患者觉得吞咽不舒服,因此并不总是耐受良好。
此外,为了获得理想的疗效,必须在短时间内大量摄入。
这可能导致开始腹痛和/或腹胀、腹泻和恶心。
-对活性成分或任何赋形剂过敏;
-胃肠道穿孔;
-严重的炎症性肠病(如溃疡性直肠结肠炎、中毒性巨结肠、克罗恩病);
-肠闭塞、亚闭塞或狭窄发作(stenotic episodes)、胃潴留、动力性肠梗阻、麻痹性肠梗阻;
-不明原因的腹痛、急性结肠炎、恶心、呕吐、蠕动明显加重或减少、直肠出血(出现一个或多个上述征象和症状需要医生进行充分深入检查,以排除存在禁忌使用缓泻剂的病状情况,参见前面几点);
-严重脱水状态;
-8岁以下且体重小于20公斤的儿童;
-在怀孕期间通常禁用。
在这方面,应注意上文所列出的大多数禁忌症本身就是需要进行肠-MRI检查的情况。
发明目的
本发明的技术目的是改进肠道病状或其他相关部门的诊断方法的状态。
该目标和这些目的均通过根据所附权利要求1的辅助饮料实现。
在其优选实施方式中,辅助饮料包含水基混合物,所述水基混合物包含80-85重量/重量%的水、0.2-0.5重量/重量%的盐、0.2%-0.5重量/重量%的琼脂(agar agar)和/或植物果胶和/或淀粉、0.3-0.5重量/重量%的玫瑰茄茶(Hibiscus sabdariffa tea)和/或含有锦葵(mallow)和/或燕麦的草本茶、15-20重量/重量%的简单碳水化合物、0.1-0.3重量/重量%的至少一种酸化剂。
盐可以包括硫酸镁,而简单碳水化合物可以包括苹果汁。
例如,酸化剂可以是柠檬汁。
它是一种患者吞咽舒适的混合物,其成分完全天然,作为造影剂,对于诊断技术(如肠-MRI等)的实施特别有效。
从属权利要求涉及本发明的优选实施方式。
具体实施方式
此外,这种饮料没有相同的禁忌症,味道更宜人,是一种完全天然的产品。
根据本发明的一个方面,该饮料为水基饮料,并且包括四种基本组分(即粘液(mucilage)、盐、多糖、碳水化合物或单糖)的混合物。
粘液具有温和通便作用。
盐具有渗透性轻泻药(osmotic purgatives)的作用。
多糖用作肠蠕动的刺激物。
最后,碳水化合物或糖是渗透性缓泻剂(osmotic laxative)。
该作用通过成像方法(如磁共振成像)确定肠系膜小肠的扩张(distension),这是评估其壁作为任何病状部位所必需的。
根据本发明的优选实施方式,辅助饮料中所含成分为如下成分:
-占至多约80-85重量%的水;
-占至多约0.2-0.5重量%的琼脂;
-占至多约0.3-0.5重量%的玫瑰茄茶(karkadè);
-占至多约15-20重量%的过滤的苹果汁;
-占至多约0.4-0.8重量%的甘露醇(mannitol);
-占至多约0.2-0.5重量%的硫酸镁;
-占至多约0.1-0.3重量%的柠檬汁。
水在混合物中具有水合作用。
更具体地说,琼脂是多糖和粘液的来源。
琼脂是刺激肠内运动的凝胶状物质。
其是一种天然胶凝剂,来源于红藻:更详细地说,其来源于多糖琼脂糖,其构成了一些红藻细胞壁的支撑结构,其被称为洋菜植物(Agarophyte),属于红藻(Rhodophyta)类;这种多糖是通过煮沸释放的。
琼脂由粘液和角叉菜胶组成,有助于将液体转化为凝胶而不需要糖的帮助;琼脂是无味的。
玫瑰茄茶(karkadè)是粘液的来源,其是舒缓且轻微的缓泻剂。
虽然玫瑰茄茶可能由于单宁的存在而具有收敛作用,但当粘液与水接触时会形成凝胶状物质,其以机械方式帮助排泄,起到温和通便作用。
硫酸镁是盐的来源。
摄入硫酸镁会提高肠道和大便的水合作用,使其具有半固态或全液态稠度,有利于排泄。
最后,甘露醇和苹果汁是简单碳水化合物/糖的来源。
甘露醇属于六元多元醇的范畴。
它是一种天然药物,用作温和缓泻剂,尤其是对儿童。
口服摄取时,甘露醇的作用类似于渗透性缓泻剂,将水吸入肠腔,并且增加粪便的体积和柔软度。
排泄物体积的增加反过来又是肠蠕动的有力刺激。
甘露醇(同样口服摄取)可用作传统蔗糖的替代性甜味剂。
它的甜味能力相当于烹饪糖的甜味能力的约50%,具有低热量和低生龋齿性(acariogenic)的优点,并且代谢不依赖于胰岛素(这是糖尿病情况下特别有用的特征);然而,其通便作用限制了其在这方面的应用。
苹果汁也有甜味作用。
柠檬汁的目的是改善饮料的味道和感官性质。
此外,柠檬汁因此在饮料中起到酸化剂的作用。
事实上,柠檬汁允许更好地管理饮料的稠度,因为在略酸性的环境中(由于柠檬汁中柠檬酸的存在),琼脂不会完全凝胶化。
柠檬汁也有防腐作用。
例如,在具有特定实际意义的本发明实施方式中,在总共约900ml的饮料中,上述成分的量约为:
-750g的水;
-3g的琼脂;
-4g的芙蓉茶(hibiscus tea);
-150g的过滤的苹果汁;
-5g的甘露醇;
-3g的硫酸镁;
-2g的柠檬汁。
在本发明的另一实施方式中,琼脂可以用植物果胶或淀粉(例如,葛根(kudzu)、玉米、大米等)替代。
在本发明的另一实施方式中,玫瑰茄茶(karkadè)可以用含有锦葵或燕麦的草本茶等替代。
在本发明的另一实施方式中,过滤的苹果汁可以用过滤的石榴汁、胡萝卜汁或蓝莓汁等替代。
在本发明的另一实施方式中,甘露醇可以用甘露糖(manna sugar)、甘露糖醇(mannite)、D-甘露醇、山梨醇或木糖醇代替。
在本发明的另一实施方式中,硫酸镁可用泻盐(epsom)或英式盐(English salt)或氯化镁或氢氧化镁等替代。
在本发明的另一实施方式中,柠檬汁可以用另一柑橘类水果(酸橙、柑橘、橙子等)的汁或柠檬酸或苹果酸等替代。
从其组成可以看出,根据本发明的饮料是完全天然的产品。
其允许获得与传统造影剂相同的性能,但是没有传统造影剂的禁忌症,并且具有更好的适口性。
在其优选实施方式中,最终制剂为微甜(得益于苹果汁和甘露醇)、清爽(refreshing)且生津止渴(thirst quenching)(得益于玫瑰茄茶和硫酸镁)、微酸(得益于柠檬汁和玫瑰茄茶)、令人愉悦的柠檬风味(得益于柠檬汁)饮料,具有由玫瑰茄茶提供的明显的红色,稠度略高,但不是凝胶状的(得益于琼脂),且略带矿物余味(得益于硫酸镁)。
本发明的目的还在于制备具有上述特征的辅助饮料的方法。
在一个实施方式中,所述方法包括:使琼脂与水混合的阶段以及使水沸腾的后续阶段,从而确保琼脂完全溶解。
随后,存在将玫瑰茄(karkadè)茶注入5分钟的阶段和随后对所得混合物进行过滤的阶段。
随后,存在如下阶段:将苹果汁、柠檬汁、硫酸镁和甘露醇添加到混合物中,并在使用本产品前使其在室温或4℃下冷却。
一旦制备好,饮料将在4℃下保存48-72小时。
在根据本发明的另一实施方式中,制备方法包括以下阶段:
琼脂、和/或植物果胶和/或淀粉热溶解;
使玫瑰茄(karkadè)茶和/或锦葵和/或燕麦草本茶与琼脂分开热溶解;
使硫酸镁和甘露醇或这两种组分的任何替代品冷溶解;
根据几何稀释原理(即,从至少浓缩的组分开始)对之前制备的溶液进行混合;
加入苹果汁溶液和/或过滤的石榴汁、胡萝卜汁、蓝莓汁;
添加酸化溶液。
制备方法是非常简单的,并且可以很容易以工业规模再现。
如上所述,本发明的目的也是将具有上述特征的辅助饮料用作口服造影剂,用于执行肠系膜小肠的磁共振成像(肠-MRI),或用于类似的诊断技术。
由此可以看出本发明是如何达到预期目的的。
具体来说,其允许获得相同的结果用于上述诊断技术的正确准备/设置,然而其不具有上述潜在的有害禁忌症。
此外,即使以相对较高的量摄入也不会对患者造成后遗症,因为其是完全天然的产品。
产品制备快速且简单,并且成本相对较低。
已经根据优选实施方式对本发明进行了描述,但是仍然可以使用等效变体而不背离所附权利要求范围。
Claims (9)
1.一种辅助饮料,其特征在于,所述辅助饮料包含水基混合物,所述水基混合物包含:
80-85重量/重量%的水;
0.2-0.5重量/重量%的盐;
0.2-0.5重量/重量%的琼脂和/或植物果胶和/或淀粉;
0.3-0.5重量/重量%的玫瑰茄茶和/或含有锦葵和/或燕麦的草本茶;
15-20重量/重量%的简单碳水化合物;
0.1-0.3重量/重量%的至少一种酸化剂。
2.如权利要求1所述的辅助饮料,其中,所述盐包括0.2-0.5重量/重量%的硫酸镁和/或泻盐和/或氯化镁和/或氢氧化镁。
3.如权利要求2所述的辅助饮料,其中,所述简单碳水化合物包括15-20重量/重量%的过滤的苹果汁和/或过滤的石榴汁、胡萝卜汁、蓝莓汁。
4.如权利要求3所述的辅助饮料,所述辅助饮料包含0.4-0.8重量/重量%的甘露醇和/或甘露糖和/或甘露糖醇和/或D-甘露醇和/或山梨醇和/或木糖醇。
5.如权利要求4所述的辅助饮料,其中,所述酸化剂包含一种或多种柑橘类水果和/或柠檬酸和/或苹果酸的果汁。
6.如权利要求5所述的饮料,其中,900ml的饮料包含:750克水、3克琼脂、4克玫瑰茄茶、150克苹果汁、5克甘露醇、3克硫酸镁、2克柠檬汁。
7.一种制备如权利要求1-6中任一项所述的辅助饮料的方法,其特征在于,所述方法包括以下阶段:
使得水和琼脂、和/或植物果胶和/或淀粉混合;
使混合物沸腾;
将玫瑰茄茶和/或锦葵和/或燕麦草本茶注入混合物中5分钟;
对混合物进行过滤;
将简单碳水化合物和酸化剂添加到混合物中;
使混合物冷却。
8.一种制备如权利要求1-6中任一项所述的辅助饮料的方法,其特征在于,所述方法包括以下阶段:
对琼脂、和/或植物果胶和/或淀粉进行热溶解;
使玫瑰茄茶和/或锦葵和/或燕麦草本茶与琼脂分开热溶解;
对盐和简单碳水化合物进行冷溶解;
根据几何稀释原理对之前制备的溶液进行混合;
添加酸化溶液。
9.如权利要求1至6中任一项所述的辅助饮料用作口服造影剂的用途,用于肠系膜小肠的磁共振成像(肠-MRI)实施。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102019000003113A IT201900003113A1 (it) | 2019-03-04 | 2019-03-04 | Bevanda coadiuvante |
IT102019000003113 | 2019-03-04 | ||
PCT/IB2020/051793 WO2020178731A1 (en) | 2019-03-04 | 2020-03-03 | Adjuvant beverage |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113660864A true CN113660864A (zh) | 2021-11-16 |
Family
ID=66867649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080021177.3A Pending CN113660864A (zh) | 2019-03-04 | 2020-03-03 | 辅助饮料 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220143191A1 (zh) |
EP (1) | EP3934442A1 (zh) |
JP (1) | JP7467492B2 (zh) |
KR (1) | KR20220002264A (zh) |
CN (1) | CN113660864A (zh) |
BR (1) | BR112021016985A2 (zh) |
CA (1) | CA3131840A1 (zh) |
DO (1) | DOP2021000181A (zh) |
IT (1) | IT201900003113A1 (zh) |
WO (1) | WO2020178731A1 (zh) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040241093A1 (en) * | 2001-11-21 | 2004-12-02 | Lauenstein Thomas C | Formulations for use in medical and diagnostic procedures |
JP2004344064A (ja) * | 2003-05-22 | 2004-12-09 | Kyoei Kogyosho:Kk | ローゼル茶及びローゼル茶の製造方法 |
WO2005018345A1 (en) * | 2003-08-18 | 2005-03-03 | Shalai Limited | New beverage and method of producing same |
US20060088616A1 (en) * | 2004-10-26 | 2006-04-27 | Miri Seiberg | Compositions containing malva sylvestris extract and use thereof on mucosal tissues |
CN101422555A (zh) * | 2008-12-23 | 2009-05-06 | 武汉名实生物医药科技有限责任公司 | 一种能通便、调畅气血、改善内分泌、延缓衰老的制剂及制备方法 |
US20130052143A1 (en) * | 2010-04-30 | 2013-02-28 | Ajinomoto Co., Inc. | Liquid preparation for oral administration to be used in ct colonography, and composition for digestive tract imaging |
US20140308374A1 (en) * | 2011-11-06 | 2014-10-16 | Jiva Pharma, Inc. | Formulations of Concentrated Prunes and Prebiotics as Laxatives and Dietary Supplements |
US20150283268A1 (en) * | 2012-10-19 | 2015-10-08 | Cosmo Technologies Ltd. | Solid oral composition containing dyes for use in endoscopic diagnosis |
US9585973B1 (en) * | 2008-06-05 | 2017-03-07 | Peter Quagliano | Palatable liquid dilution vehicles for oral contrast agents |
US20180008626A1 (en) * | 2015-01-27 | 2018-01-11 | Apharm S.R.L. | Combination of hyaluronic acid and macrogol and pharmaceutical compositions containing it |
US20180147301A1 (en) * | 2016-11-28 | 2018-05-31 | Cosmo Technologies Ltd. | Solid oral composition containing dyes |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5120527A (en) * | 1989-10-19 | 1992-06-09 | King Chuen Peter Li | Paramagnetic oil emulsions as mri contrast agents |
US20180221276A1 (en) * | 2017-02-07 | 2018-08-09 | Drink NOVE, LLC | Wellness drink and method of manufacture |
-
2019
- 2019-03-04 IT IT102019000003113A patent/IT201900003113A1/it unknown
-
2020
- 2020-03-03 CA CA3131840A patent/CA3131840A1/en active Pending
- 2020-03-03 JP JP2021551547A patent/JP7467492B2/ja active Active
- 2020-03-03 US US17/434,964 patent/US20220143191A1/en active Pending
- 2020-03-03 BR BR112021016985A patent/BR112021016985A2/pt unknown
- 2020-03-03 CN CN202080021177.3A patent/CN113660864A/zh active Pending
- 2020-03-03 KR KR1020217029804A patent/KR20220002264A/ko unknown
- 2020-03-03 WO PCT/IB2020/051793 patent/WO2020178731A1/en unknown
- 2020-03-03 EP EP20716103.5A patent/EP3934442A1/en active Pending
-
2021
- 2021-07-29 DO DO2021000181A patent/DOP2021000181A/es unknown
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040241093A1 (en) * | 2001-11-21 | 2004-12-02 | Lauenstein Thomas C | Formulations for use in medical and diagnostic procedures |
JP2004344064A (ja) * | 2003-05-22 | 2004-12-09 | Kyoei Kogyosho:Kk | ローゼル茶及びローゼル茶の製造方法 |
WO2005018345A1 (en) * | 2003-08-18 | 2005-03-03 | Shalai Limited | New beverage and method of producing same |
US20060088616A1 (en) * | 2004-10-26 | 2006-04-27 | Miri Seiberg | Compositions containing malva sylvestris extract and use thereof on mucosal tissues |
US9585973B1 (en) * | 2008-06-05 | 2017-03-07 | Peter Quagliano | Palatable liquid dilution vehicles for oral contrast agents |
CN101422555A (zh) * | 2008-12-23 | 2009-05-06 | 武汉名实生物医药科技有限责任公司 | 一种能通便、调畅气血、改善内分泌、延缓衰老的制剂及制备方法 |
US20130052143A1 (en) * | 2010-04-30 | 2013-02-28 | Ajinomoto Co., Inc. | Liquid preparation for oral administration to be used in ct colonography, and composition for digestive tract imaging |
US20140308374A1 (en) * | 2011-11-06 | 2014-10-16 | Jiva Pharma, Inc. | Formulations of Concentrated Prunes and Prebiotics as Laxatives and Dietary Supplements |
US20150283268A1 (en) * | 2012-10-19 | 2015-10-08 | Cosmo Technologies Ltd. | Solid oral composition containing dyes for use in endoscopic diagnosis |
US20180008626A1 (en) * | 2015-01-27 | 2018-01-11 | Apharm S.R.L. | Combination of hyaluronic acid and macrogol and pharmaceutical compositions containing it |
US20180147301A1 (en) * | 2016-11-28 | 2018-05-31 | Cosmo Technologies Ltd. | Solid oral composition containing dyes |
Non-Patent Citations (3)
Title |
---|
VITHYA VARAVITHYA, MD ET AL: "The Efficacy of Roselle (Hibicus Sabdariffa Linn.) Flower Tea as Oral Negative Contrast Agent for MRCP Study", 《J MED ASSOC THAI》, vol. 88, pages 35 - 41 * |
李升锋等: "玫瑰茄花萼营养和药理作用研究进展", 《食品研究与开发》, vol. 27, no. 10, pages 129 - 133 * |
陈钟英主编: "《临床药物手册》", pages: 423 * |
Also Published As
Publication number | Publication date |
---|---|
JP7467492B2 (ja) | 2024-04-15 |
BR112021016985A2 (pt) | 2021-11-30 |
EP3934442A1 (en) | 2022-01-12 |
IT201900003113A1 (it) | 2020-09-04 |
CA3131840A1 (en) | 2020-09-10 |
US20220143191A1 (en) | 2022-05-12 |
JP2022522361A (ja) | 2022-04-18 |
KR20220002264A (ko) | 2022-01-06 |
WO2020178731A1 (en) | 2020-09-10 |
DOP2021000181A (zh) | 2021-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6103268A (en) | Administering osmotic colonic evacuant containing a picosulfate | |
CN103495187B (zh) | 一种用于b超的中药胃肠助影剂及其制备方法 | |
CN102441178A (zh) | 做b超使用的中药助影剂 | |
CN113660864A (zh) | 辅助饮料 | |
EP2387408A1 (en) | Energetic nutritional composition comprising a laxative, electrolytes and carbohydrates | |
WO2007013093A2 (en) | Laxative formulation containing a triphala extract | |
US9895406B2 (en) | Homeopathic remedies and methods for enhancing weight loss | |
ES2896689T3 (es) | Composición para el tratamiento del estreñimiento | |
ES2896702T3 (es) | Composición para el tratamiento del estreñimiento | |
KR100534386B1 (ko) | 녹차가루 및 차전차피를 주성분으로 하는 변비 개선용식품조성물 | |
CN104771621B (zh) | 一种治疗咳喘的中药组方、制备方法及其应用 | |
Mills | Functional insufficiency of the suprarenal glands | |
EP3697383B1 (en) | Composition for treating constipation | |
Chopra | Plantago Ovata—Ispaghul—In Chronic Diarrhœas and Dysenteries | |
JP2019043900A (ja) | ラクツロースを有効成分とする便秘症治療剤 | |
CN105617276A (zh) | 一种治疗直肠脱垂的药物组合物 | |
CN107007671A (zh) | 一种改善或治疗放射性肠炎的组合物及其制备方法和用途 | |
CN114903960A (zh) | 一种治疗慢性胃炎的中药组合物及其制备方法 | |
AU2002312652B2 (en) | Laxative preparation | |
CN105056254A (zh) | 一种b超助影剂及其制备方法和用途 | |
Thompson | Constipation and catharsis. | |
JP2023105249A (ja) | 胃部不快感改善剤及び尿意抑制剤 | |
CN112156162A (zh) | 一种保护胃粘膜的药物及其制备方法 | |
NZ529895A (en) | Laxative preparation | |
CN105535888A (zh) | 克拉霉素复方组合物及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |